Avalyn Pharma grants director options for 31K shares

A director of Avalyn Pharma received a multi‑year stock option grant as part of equity-based compensation.

Available on EDGAR 09/17/2026 - 04:10 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Avalyn Pharma Inc. (AVLN) reported that director Robert J. Meyer received a stock option award on September 15, 2026. The option covers 31,182 shares of common stock at an exercise price of $34.28 per share, expiring on September 14, 2036. The option vests in three equal annual installments after the grant date, conditioned on his continued service.

Insider Trade Summary

Grant/Award: 31,182 shares

Grant/Award 1 txn

Insider Meyer Robert J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	31,182	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,182 options (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 31,182 options (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest and become exercisable in three equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 31,182 shares Exercise price: $34.28 per share Expiration date: September 14, 2036 +2 more

5 metrics

Stock options granted 31,182 shares Stock option award to director Robert J. Meyer on September 15, 2026

Exercise price $34.28 per share Exercise price for the 31,182-share stock option grant

Expiration date September 14, 2036 Option term for the reported stock option grant

Post-grant option holdings 31,182 shares Total directly held options reported for Robert J. Meyer after the grant

Vesting installments Three equal annual tranches Vesting schedule conditioned on continued service

Key Terms

Stock option, Exercise price, Vesting, Common stock

4 terms

Stock option financial

"Director Robert J. Meyer received a stock option award as equity compensation."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Exercise price financial

"The option carries an exercise price of $34.28 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Vesting financial

"The shares underlying this option vest in three equal annual installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common stock financial

"The stock option relates to shares of Avalyn Pharma common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalyn Pharma (AVLN) disclose for Robert J. Meyer?

Avalyn Pharma disclosed that director Robert J. Meyer received a stock option grant for 31,182 shares of common stock on September 15, 2026, as equity compensation. The award carries an exercise price of $34.28 per share and expires on September 14, 2036.

What is the exercise price of the new stock options reported by AVLN?

The reported stock option grant to director Robert J. Meyer has an exercise price of $34.28 per share. This is the price at which he may purchase Avalyn Pharma common shares upon exercising the option, subject to vesting and other terms.

How many shares are covered by the Avalyn Pharma (AVLN) stock option grant?

The stock option grant to director Robert J. Meyer covers 31,182 shares of Avalyn Pharma common stock. Following this grant, his directly held option position reported in this filing is also 31,182 shares.

What is the vesting schedule for the AVLN stock options granted to Robert J. Meyer?

The options vest and become exercisable in three equal annual installments after the grant date. Vesting is subject to Robert J. Meyer’s continued service with Avalyn Pharma on each vesting date.

When do the newly granted Avalyn Pharma (AVLN) options expire?

The stock options granted to director Robert J. Meyer expire on September 14, 2036, providing a long-dated window during which, once vested, they may be exercised at the stated exercise price.

Were the AVLN insider option grants made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this stock option grant to director Robert J. Meyer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyer Robert J.

(Last) (First) (Middle)

C/O AVALYN PHARMA INC.

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$34.28	09/15/2026		A		31,182		(1)	09/14/2036	Common Stock	31,182	$0.00	31,182	D

Explanation of Responses:

1. The shares underlying this option vest and become exercisable in three equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Douglas Carlson, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)